NP / PA
Commonwealth Pain Associates, PLLC
Commonwealth Pain Associates, PLLC was paid $42.20M by Medicaid between Jan 2018 and Dec 2024, across 78 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 21% of everything it billed.
33Billing provider infoCOMMONWEALTH PAIN ASSOCIATES, PLLC
LOUISVILLE, KY 40207
LOUISVILLE, KY 40207
33aNPI1306280177assigned 04/24/2013
33bProvider typeMedical Physician Assistant
28Total paid$42.20M
24GClaims1,218,829
24DCodes billed78
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Medical Physician Assistant providers in Kentucky
Rank by total paid#1 of 45
Median peer was paid$258K
This provider vs. median164×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 106,181 | $2.74M | |
| 2019 | 137,175 | $4.43M | |
| 2020 | 174,588 | $5.96M | |
| 2021 | 208,154 | $6.87M | |
| 2022 | 197,318 | $7.03M | |
| 2023 | 195,194 | $7.72M | |
| 2024incomplete | 200,219 | $7.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 21% | 228,001 | 205,551 | $8.80M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 14% | 91,330 | 81,783 | $6.10M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 247,554 | 217,751 | $6.02M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.8% | 81,410 | 74,801 | $2.45M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 5.4% | 29,701 | 26,825 | $2.30M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 4.8% | 17,541 | 15,493 | $2.02M |
| 64635 | 4.1% | 7,408 | 6,579 | $1.75M | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 4.1% | 41,613 | 36,617 | $1.75M |
| 64483 | 3.9% | 13,110 | 11,621 | $1.64M | |
| 80305 | 3.4% | 231,378 | 202,349 | $1.44M | |
| 27096 | 2.7% | 7,065 | 6,462 | $1.15M | |
| 64636 | 2.7% | 7,756 | 6,394 | $1.13M |
66 more codes
| 64493 | 2.4% | 10,783 | $1.01M | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.8% | 8,425 | $771K |
| 64494 | 1.2% | 11,145 | $510K | |
| 62323 | 1.1% | 4,173 | $460K | |
| J7320 | Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg | <1% | 205 | $416K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 15,011 | $276K |
| 62321 | <1% | 1,962 | $256K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 4,502 | $231K |
| 77002 | <1% | 5,864 | $213K | |
| 20610 | <1% | 6,387 | $199K | |
| 64484 | <1% | 2,071 | $147K | |
| 01992 | <1% | 3,124 | $142K | |
| L0650 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | <1% | 207 | $105K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 11,167 | $80K |
| 64495 | <1% | 1,368 | $80K | |
| 99442 | <1% | 3,933 | $73K | |
| 99490 | Ccm add 20min | <1% | 27,580 | $60K |
| 99484 | <1% | 2,828 | $59K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,490 | $59K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 15,659 | $56K |
| 20553 | <1% | 1,869 | $50K | |
| 01940 | <1% | 859 | $49K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,297 | $45K |
| 99441 | <1% | 3,323 | $40K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 8,551 | $37K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,415 | $37K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,138 | $34K |
| 99439 | <1% | 9,467 | $19K | |
| 99152 | <1% | 922 | $18K | |
| 72114 | <1% | 527 | $16K | |
| 64490 | <1% | 144 | $15K | |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 235 | $14K |
| 96103 | <1% | 1,310 | $12K | |
| 99443 | <1% | 309 | $11K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,949 | $11K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,402 | $8K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 22,667 | $6K |
| 64491 | <1% | 122 | $6K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 400 | $5K |
| 72052 | <1% | 160 | $5K | |
| 96146 | <1% | 2,618 | $3K | |
| 98977 | <1% | 108 | $3K | |
| 64633 | <1% | 17 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 113 | $2K |
| G2058 | Chronic care management services, each additional 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (list separately in addition to code for primary procedure). (do not report g2058 for care management services of less than 20 minutes additional to the first 20 minutes of chronic care management services during a calendar month). (use g2058 in conjunction with 99490). (do not report 99490, g2058 in the same calendar month as 99487, 99489, 99491)). | <1% | 1,488 | $2K |
| 64634 | <1% | 17 | $2K | |
| 20552 | <1% | 73 | $2K | |
| 97014 | <1% | 187 | $1K | |
| 98967 | <1% | 142 | $1K | |
| 73560 | <1% | 77 | $994.65 | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 67 | $982.08 |
| 96127 | <1% | 288 | $938.55 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 254 | $786.17 |
| 97161 | <1% | 19 | $754.86 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 21 | $617.35 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 32 | $589.91 |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 196 | $462.04 |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 12 | $434.26 |
| 97162 | <1% | 13 | $396.38 | |
| 98968 | <1% | 21 | $210.84 | |
| 96160 | <1% | 139 | $195.21 | |
| 98966 | <1% | 35 | $173.11 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14 | $157.29 |
| 98975 | <1% | 20 | $145.69 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 28 | $40.37 |
| 99072 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLEWIS, JASON (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Calvary Cab Services, INC | Poughkeepsie, NY | $29K |
| Commonwealth Pain Associates PLLC | London, KY | $8K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.